Personalized drug therapy based on genetics. Possibilities and examples from clinical practice
BACKGROUND: Pharmacogenetics are an important component in the individualization of treatment; however, pharmacogenetic diagnostics have so far not been used to any great extent in clinical practice. A consistent consideration of individual patient factors, such as pharmacogenetics may help to improve drug therapy and increase individual safety and efficacy aspects.
OBJECTIVE: A brief summary of structures and effects of genetic variations on drug efficacy is presented. Some frequently prescribed pharmaceuticals are specified. Furthermore, the feasibility of pharmacogenetic diagnostics and dose recommendations in the clinical practice are described.
CURRENT DATA: The European Medicines Agency (EMA) as the European approval authority has already extended the drug labels of more than 70 pharmaceuticals by information on pharmacogenetic biomarkers and the U.S. Food and Drug Administration (FDA) more than 150. This is a crucial step towards targeted medicine. Guidelines on dose and therapy adjustments are provided by the Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network.
CONCLUSION: It is fundamental to consider individual patient factors for successful drug therapy. Dose and therapy recommendations based on pharmacogenetic diagnostics are highly important for individualization as well as improvement of safety and efficiency of drug therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:57 |
|---|---|
| Enthalten in: |
Der Internist - 57(2016), 3 vom: 07. März, Seite 289-97 |
| Sprache: |
Deutsch |
|---|
| Weiterer Titel: |
Personalisierte Arzneitherapie auf genetischer Grundlage. Möglichkeiten und Beispiele aus der Praxis |
|---|
| Beteiligte Personen: |
Stingl, J C [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Dose recommendations |
|---|
| Anmerkungen: |
Date Completed 13.12.2016 Date Revised 13.11.2018 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00108-015-0013-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM257028137 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM257028137 | ||
| 003 | DE-627 | ||
| 005 | 20231224181929.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1007/s00108-015-0013-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0856.xml |
| 035 | |a (DE-627)NLM257028137 | ||
| 035 | |a (NLM)26830424 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 100 | 1 | |a Stingl, J C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Personalized drug therapy based on genetics. Possibilities and examples from clinical practice |
| 246 | 3 | 3 | |a Personalisierte Arzneitherapie auf genetischer Grundlage. Möglichkeiten und Beispiele aus der Praxis |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.12.2016 | ||
| 500 | |a Date Revised 13.11.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Pharmacogenetics are an important component in the individualization of treatment; however, pharmacogenetic diagnostics have so far not been used to any great extent in clinical practice. A consistent consideration of individual patient factors, such as pharmacogenetics may help to improve drug therapy and increase individual safety and efficacy aspects | ||
| 520 | |a OBJECTIVE: A brief summary of structures and effects of genetic variations on drug efficacy is presented. Some frequently prescribed pharmaceuticals are specified. Furthermore, the feasibility of pharmacogenetic diagnostics and dose recommendations in the clinical practice are described | ||
| 520 | |a CURRENT DATA: The European Medicines Agency (EMA) as the European approval authority has already extended the drug labels of more than 70 pharmaceuticals by information on pharmacogenetic biomarkers and the U.S. Food and Drug Administration (FDA) more than 150. This is a crucial step towards targeted medicine. Guidelines on dose and therapy adjustments are provided by the Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network | ||
| 520 | |a CONCLUSION: It is fundamental to consider individual patient factors for successful drug therapy. Dose and therapy recommendations based on pharmacogenetic diagnostics are highly important for individualization as well as improvement of safety and efficiency of drug therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Dose recommendations | |
| 650 | 4 | |a Drug therapy, safety | |
| 650 | 4 | |a Guidelines | |
| 650 | 4 | |a Personalized medicine | |
| 650 | 4 | |a Pharmacogenetics | |
| 650 | 7 | |a Genetic Markers |2 NLM | |
| 700 | 1 | |a Just, K S |e verfasserin |4 aut | |
| 700 | 1 | |a Kaumanns, K |e verfasserin |4 aut | |
| 700 | 1 | |a Schurig-Urbaniak, M |e verfasserin |4 aut | |
| 700 | 1 | |a Scholl, C |e verfasserin |4 aut | |
| 700 | 1 | |a von Mallek, D |e verfasserin |4 aut | |
| 700 | 1 | |a Brockmöller, J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Der Internist |d 1960 |g 57(2016), 3 vom: 07. März, Seite 289-97 |w (DE-627)NLM000030767 |x 1432-1289 |7 nnns |
| 773 | 1 | 8 | |g volume:57 |g year:2016 |g number:3 |g day:07 |g month:03 |g pages:289-97 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00108-015-0013-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 57 |j 2016 |e 3 |b 07 |c 03 |h 289-97 | ||